Medical News

August 26, 2004 — Research and Markets announces the addition of “Therapeutic Vaccines” to its offerings.

With the worldwide prevalence of cancer and HIV/AIDS estimated at approximately 17 million and 46 million people respectively in 2004, there is increasing demand for effective therapeutics to delay disease progression, reduce dependence on highly-toxic drug regimens, and improve the quality of life for patients.

The worldwide market for therapeutic vaccines is estimated to be$80M in 2004 and grow at an explosive compound annual growth rate of 92% to reach approximately $2.1B in 2009. Over the next five years, autologous vaccines will emerge, establish cancer vaccines as a viable and desired treatment option, and grow to be the major class in this market. Other classes of vaccines, such as monoclonal antibodies and allogeneicvaccines for cancer, will garner small market shares mainly because of geographic restrictions and limited patient populations.

This report includes in-depth analysis of physician perspectives and incorporates company profiles and assessments of the challenges, and strategic options facing companies developing therapeutic vaccines. In addition, the study provides the financial analysis and detailed assumptions used to determine major company market shares and to estimate the industry-wide revenue forecast.

For a thorough analysis of this important market, the report:
- evaluates current and emerging therapeutic vaccines
- assesses the results of a 12 physician panel survey and examines their views on current cancer treatments and the need for therapeutic vaccines
- provides a market forecast and revenue model from 2004 through 2009 with detailed assumptions for each therapeutic and the industry
- nalyzes the strategic positioning of 9 emerging therapeutic vaccines
- profiles 16 companies developing vaccines
- identifies multiple development trends and challenges
- provides strategic options for therapeutic vaccine companies looking to enter the market and expand revenues

For a complete index of this report click on http://www.researchandmarkets.com/reports/222270

About Research and Markets Ltd.
Research and Markets Ltd. are Europe’s largest resource for market research. R&M distribute thousands of major research publications from the world’s leading publishers, consultants and market analysts. R&M provide you with the latest forecasts on international and regional markets, key industries, the top companies, new products and the latest market trends.

For additional information on ResearchandMarkets.com, their range of reports or their value-added services, visit their web site at http://www.researchandmarkets.com or mailto:press@researchandmarkets.com

August 26, 2004 — Research and Markets announces the addition of “Therapeutic Vaccines” to its offerings.

With the worldwide prevalence of cancer and HIV/AIDS estimated at approximately 17 million and 46 million people respectively in 2004, there is increasing demand for effective therapeutics to delay disease progression, reduce dependence on highly-toxic drug regimens, and improve the quality of life for patients.

The worldwide market for therapeutic vaccines is estimated to be$80M in 2004 and grow at an explosive compound annual growth rate of 92% to reach approximately $2.1B in 2009. Over the next five years, autologous vaccines will emerge, establish cancer vaccines as a viable and desired treatment option, and grow to be the major class in this market. Other classes of vaccines, such as monoclonal antibodies and allogeneicvaccines for cancer, will garner small market shares mainly because of geographic restrictions and limited patient populations.

This report includes in-depth analysis of physician perspectives and incorporates company profiles and assessments of the challenges, and strategic options facing companies developing therapeutic vaccines. In addition, the study provides the financial analysis and detailed assumptions used to determine major company market shares and to estimate the industry-wide revenue forecast.

For a thorough analysis of this important market, the report:
- evaluates current and emerging therapeutic vaccines
- assesses the results of a 12 physician panel survey and examines their views on current cancer treatments and the need for therapeutic vaccines
- provides a market forecast and revenue model from 2004 through 2009 with detailed assumptions for each therapeutic and the industry
- nalyzes the strategic positioning of 9 emerging therapeutic vaccines
- profiles 16 companies developing vaccines
- identifies multiple development trends and challenges
- provides strategic options for therapeutic vaccine companies looking to enter the market and expand revenues

For a complete index of this report click on http://www.researchandmarkets.com/reports/222270

About Research and Markets Ltd.
Research and Markets Ltd. are Europe’s largest resource for market research. R&M distribute thousands of major research publications from the world’s leading publishers, consultants and market analysts. R&M provide you with the latest forecasts on international and regional markets, key industries, the top companies, new products and the latest market trends.

For additional information on ResearchandMarkets.com, their range of reports or their value-added services, visit their web site at http://www.researchandmarkets.com or mailto:press@researchandmarkets.com